Literature DB >> 2958176

Salutary action of nicorandil, a new antianginal drug, on myocardial metabolism during ischemia and on postischemic function in a canine preparation of brief, repetitive coronary artery occlusions: comparison with isosorbide dinitrate.

G M Pieper1, G J Gross.   

Abstract

The effects of two antianginal drugs, nicorandil and isosorbide dinitrate (ISDN), on metabolism and function of the ischemic myocardium were studied in a preparation of multiple coronary occlusions in barbital-anesthetized dogs. The preparation consisted of three 5 min occlusions of the left anterior descending coronary artery interspersed by 30 min of reperfusion. An equihypotensive dose of nicorandil (7.5 micrograms/kg/min) or ISDN (12.5 micrograms/kg/min) was infused 15 min before and during the second occlusion period. Hemodynamics, myocardial segment shortening (%SS), tissue blood flow, and myocardial oxygen consumption were determined throughout. Uptake of free fatty acids (FFA), glucose, and lactate were determined during control and ischemic periods. At the end of the final 30 min reperfusion period, biopsy samples of transmural tissue were taken for analysis of phosphocreatine, adenine nucleotides, and total tissue water content. No major hemodynamic changes were produced by either drug except for a 5 to 10 mm Hg decrease in mean aortic pressure. Compared with untreated and ISDN-treated hearts, hearts of dogs treated with nicorandil exhibited reversal of a significant increase in FFA uptake during recurrent ischemia. This was accompanied by an attenuation of the increase in oxygen extraction and CO2 production in the ischemic zone by nicorandil, but not by ISDN. Nicorandil, but not ISDN, improved %SS during reperfusion. Endocardial ATP and total adenine nucleotides were preserved in both nicorandil- and ISDN-treated hearts. Tissue edema was also attenuated by both compounds. Thus, nicorandil improved both function and metabolism during recurrent myocardial ischemia independent of a hemodynamic effect, whereas ISDN only attenuated the loss of adenine nucleotides and increase in tissue water.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2958176     DOI: 10.1161/01.cir.76.4.916

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  10 in total

Review 1.  Electrophysiologic effects of potassium channel openers.

Authors:  W Haverkamp; M Borggrefe; G Breithardt
Journal:  Cardiovasc Drugs Ther       Date:  1995-03       Impact factor: 3.727

2.  Nicorandil ameliorates posttransplant dysfunction in cardiac allografts harvested from non-heart-beating donors.

Authors:  Makoto Mohri; Kotaro Suehiro; Shu Yamamoto; Hiroki Yamaguchi; Kozo Ishino; Shunji Sano
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2002-10

3.  Nicorandil and cardiovascular performance in anaesthetized pigs with a concentric coronary artery stenosis.

Authors:  L M Sassen; L K Soei; T J Heere; L J van Woerkens; P R Saxena; P D Verdouw
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-12       Impact factor: 3.000

Review 4.  Pharmacology and therapeutic effects of nicorandil.

Authors:  M Kinoshita; K Sakai
Journal:  Cardiovasc Drugs Ther       Date:  1990-08       Impact factor: 3.727

5.  Nicorandil induces late preconditioning against myocardial infarction in conscious rabbits.

Authors:  Xian-Liang Tang; Yu-Ting Xuan; Yanqing Zhu; Gregg Shirk; Roberto Bolli
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-12-18       Impact factor: 4.733

6.  Protection by nicorandil against the dysfunction of the central vagal baroreflex system following transient global cerebral ischaemia in dogs.

Authors:  J Kurihara; N Ochiai; H Kato
Journal:  Br J Pharmacol       Date:  1993-08       Impact factor: 8.739

7.  In vitro protective effects of nicorandil on hypothermic injury to immature cardiac myocytes: comparison with nitroglycerin.

Authors:  H Orita; M Fukasawa; S Hirooka; K Fukui; M Kohi; M Washio
Journal:  Cardiovasc Drugs Ther       Date:  1994-02       Impact factor: 3.727

Review 8.  Nicorandil. A review of its pharmacology and therapeutic efficacy in angina pectoris.

Authors:  J Frampton; M M Buckley; A Fitton
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

9.  Anti-free-radical and neutrophil-modulating properties of the nitrovasodilator, nicorandil.

Authors:  G M Pieper; G J Gross
Journal:  Cardiovasc Drugs Ther       Date:  1992-06       Impact factor: 3.727

10.  Nicorandil suppressed myocardial purine metabolism during exercise in patients with angina pectoris.

Authors:  K Ogino; S Osaki; N Noguchi; H Kitamura; H Omodani; M Kato; I Hisatome; T Matsumoto; T Kinugawa; H Miyakoda
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.